MolDX: DecisionDx-UM (Uveal Melanoma)

DecisionDx-UM is covered only for management of newly diagnosed, confirmed uveal melanoma patients without evidence of metastatic disease to determine metastatic risk and guide surveillance and oncology referral. Coverage is limited to this clinical scenario; the policy does not specify testing frequency, detailed documentation forms, or prior authorization requirements and recommends referral preferably to a melanoma-expert medical oncologist.

"DecisionDx-UM (Castle Bioscience) is covered for management of newly diagnosed uveal melanoma to determine metastatic risk and to guide surveillance and referral to medical oncology."

Sign up to see full coverage criteria, indications, and limitations.